D-0037-2026 Class II Ongoing

Recalled by Graviti Pharmaceuticals Private Limited — Hyderabad

FDA drug recall D-0037-2026 was initiated by Graviti Pharmaceuticals Private Limited on Sep 15, 2025 and is designated Class II. Reason for recall: Failed Tablet/Capsule Specifications The recall status is ongoing. Affected quantity: 46,512/30 count bottles.

Recall details

Product Type
Drugs
Report Date
Oct 29, 2025
Initiation Date
Sep 15, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
46,512/30 count bottles

Product description

Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg, 30-count bottles, Rx Only, Mfd. by: Graviti Pharmaceuticals Private Limited, Sangareddy, Telangana, India, Dist. by: Rising Phar, NDC 16571-863-03.

Reason for recall

Failed Tablet/Capsule Specifications

Distribution pattern

Product was distributed to 1 distributor and 16 wholesalers/pharmacy retailers nationwide.

Code information

Batch # BPB124341A, Exp date: 10/2026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0037-2026
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0037-2026. Report a data issue: hello@regdatalab.com.